A Trial to Evaluate the Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age
Key facts
- Who runs it
- GlaxoSmithKline
- Where
- Australia4 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 1
- People taking part
- 127 people enrolled
- Started
- 12 Aug 2025
- Ended
- 6 May 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Pn-MAPS30plus
- PCV20
- Record updated
- 5 June 2026
Who can take part
- Age
- 50 years to 64 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol
- Written or witnessed/thumb printed informed consent obtained from the participant prior to performance of any trial-specific procedure
- Healthy male and female participants between and including 50 through 64 YOA at the time of Informed consent form (ICF) signature
- Female participants of childbearing potential may be enrolled if they practice adequate contraception and have a negative pregnancy test prior to study intervention administration
Who cannot take part
- Use of any investigational or non-registered product other than the study interventions during the period beginning 30 days before the study intervention administration
- History of previous vaccination with any pneumococcal vaccine
- Receipt of blood or plasma products or immunoglobulins, from 90 days before study intervention administration, or planned receipt within 30 days of study intervention administration
- Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and/or planned use of long-acting immune-modifying treatments at any time up to the end of the trial
- History of microbiologically proven Invasive Pneumococcal Disease (IPD) caused by S. pneumoniae within the past 3 years
- History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention(s)
- Any confirmed or suspected immunosuppressive or immunodeficient condition
- Hypersensitivity to latex
- Clinical conditions representing a contraindication to intramuscular vaccination, and blood collection
- Documented history of Human immunodeficiency virus (HIV)-positive participant
- Acute or unstable chronic clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, or metabolic conditions as determined by the investigator
- Recurrent history of uncontrolled neurological or any neuroinflammatory disorders
- Any behavioural or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with trial participation
- History of potential immune-mediated disorders (pIMDs)
- Any other clinical condition that, might pose additional risk to the participant
- History of chronic alcohol consumption and/or drug abuse, based on investigator judgment
- Pregnant or lactating female participant
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This clinical study is designed to evaluate an investigational pneumococcal vaccine named Pn-MAPS30plus. The vaccine is designed to stimulate the immune system to produce antibodies against various serotypes of the S. pneumoniae bacteria, potentially aiding the body in fighting infection upon exposure. Pn-MAPS30plus aims to broaden protection by covering more serotypes than currently licensed pneumococcal vaccines. The study's purpose is to determine whether the vaccine is safe, well-tolerated, and effective in inducing immune responses against S. pneumoniae.
The 2 groups in the trial
- Pn-MAPS30plus GroupTreatment being tested
Participants receive a single dose of Pn-MAPS30plus on Day 1.
Treatment: Pn-MAPS30plus
- PCV20 GroupExisting treatment, for comparison
Participants receive a single dose of PCV20 on Day 1.
Treatment: PCV20
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1, Observer-Blind, Randomized, Active Controlled Trial to Evaluate the Safety and Immunogenicity of An Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age
- Record updated
- 5 June 2026